• We are catalysts for innovation, commercialising next-generation technologies developed by

    The University of Manchester’s world-class research base

    • £360m+ invested by venture funders

    • 40+ spin-out companies created

    • 7,500+ licences and IP partnerships concluded

    • 4,000+ invention disclosures received

    • £115m+ IP and R&D revenue generated for the University

  • We are catalysts for innovation, commercialising next-generation technologies developed by The University of Manchester’s world-class research base

    • £300m+ invested by venture funders since 2004

    • 40+ spin-out companies created

    • 4,800+

      licences and IP partnerships concluded

    • 3,700+ invention disclosures received

    • 1,300+ jobs generated across various industry sectors

    • £105m+ IP and R&D revenue generated for the University

Archive for November, 2012

Manchester wins three awards at the 2012 Northwest Bionow Awards

Over 280 people from the Northwest’s biomedical sector gathered on 29th November at the 11th Northwest Biomedical Awards at Mere Golf and Country Club, Cheshire. This prestigious awards dinner celebrates key achievements from companies and individuals who have made a significant contribution to the biomedical sector during 2012.   

The judging panel which decided the winners consisted of representatives from each of the award sponsors and considered over 60 applications.

The University of Manchester winners were:

University of Manchester spin-out, Phagenesis Ltd, Phagenyx – Healthcare Project of the Year.

University of Manchester, Microsensor – Biomedical Project of the Year.

Euprotec Ltd – Service Company of the Year

The complete list of winners is as follows:

Start-Up Company of the Year
Incanthera Ltd

Promising Technologist of the Year
Dr Nick Bryan, CellCap Technologies Ltd

Healthcare Project of the Year
Phagenesis Ltd, Phagenyx

Product or Service of the Year
Biofortuna Ltd, Stable Molecular Diagnostic PCR reagents

Biomedical Project of the Year
University of Manchester, Microsensor

Investment Deal of the Year
Clinigen Group Plc, Clinigen Group IPO

Service Company of the Year
Euprotec Ltd

Company of the Year
Eden Biodesign

For more information about Bionow, please visit www.bionow.co.uk

Graphene Bioscience Interdisciplinary Grand Challenges at The University of Manchester

Funding available: Graphene Bioscience Interdisciplinary Grand Challenges

The University of Manchester has committed £200K to pump-prime investigations into how Graphene-based solutions might be applied to biomedical/life science problems.

Applications for pilot studies (up to 12 months in duration) are encouraged from researchers across the University.

Major challenge areas for use of Graphene in life science/biomedical applications:

> Biointegration

> Biological barriers

> Biosensors

> Enzyme/material based hybrid systems

> Selective adsorptive properties of Graphene


Although the above areas provide the main focus of this call they are not exclusive and alternative

transformative ideas are also welcomed.

For further info on the scheme go to:  www.mhs.manchester.ac.uk/research/support/deanery


Application process:

Outline applications and completion of the Graphene Clinic Doodle Poll by 4pm Thursday 10th January 2013

Full applications by 4pm Thursday 14th February 2013

Please submit outline/full applications to the FMHS Research Deanery: RD@manchester.ac.uk. 

General enquiries: Kay.Hodgson@manchester.ac.uk /0161 306 0552

So2Speak launches new app at international convention

University of Manchester oro-motor exercise app developer, So2Speak, exhibited to over 12,000 delegates at the 2012 ASHA Convention which took place at the Georgia World Congress Center in Atlanta from November 15–17.

The annual American Speech-Language-Hearing Association (ASHA) convention unites speech-language pathologists, audiologists, and speech, language and hearing scientists to learn about the latest evidence-based research techniques, new tools and resources.

So2Speak showcased its iPad and iPhone oro-motor exercise app – a brand new tool which allows speech and language professionals to design tailored programmes for any patient who would benefit from oral motor exercise therapy, such as individuals suffering from a neurological condition or following surgery. The event was attended by Dr Ed Maughfling, UMIP licensing manager, and by Claire Mitchell, creator of the app.

Dr Ed Maughfling comments: “This was a “most-go” event for So2Speak, providing a unique opportunity to showcase our app to potential customers, to receive feedback from them and to learn from other speech and language app developers.”

Claire Mitchell comments: “The feedback about So2Speak that we got at the convention was overwhelmingly positive and enthusiastic. Therapists loved the individual patient settings and the video camera function and really liked the idea of monitoring patient self-evaluation and the use of stats to monitor outcome. I am really keen for people to hear about this app as I feel it will improve the quality of intervention for people needing these exercises. Future apps from So2Speak will build on the same features we have used in this one to provide high standards of therapy to people.”

For further information, please see www.so2speakapp.com or visit the Apple App Store to download.



Manchester Team Triumphs in Competition to be Biotechnology Stars of the Future

A Manchester team has secured a place in the final of a national competition to find the entrepreneurial bioscientists of the future.

Enzomax beat off stiff competition from 15 other teams from universities and institutes around the UK in the Biotechnology Young Entrepreneurs Scheme (Biotechnology YES) 2012 competition. They will fly the flag for Manchester in December in London at the UK finals where the winning team will collect £1,000, an invitation to attend the BIA Gala Dinner and the opportunity to attend the premier regional US Business Plan Competition at Rice University in Houston, Texas.

Enzomax (Matthew Styles, Anna-Winona Struck; Sarah Shepherd; Brian Law; James Leigh) have a proprietary platform technology, known as Enzomax SHIELD™, which they use to deliver cost-effective solutions for maximising the performance of enzymes in industrial biotechnology.

Enzomax will be joined by CosmoClear (University College London) who also secured a place in the December final. CosmoClear’s product provides a unique alternative to the treatment of oily complexions as it is safe, natural and effective

The competition, hosted by The University of Manchester’s Innovation Centre (UMIC) on day one and organised jointly by the Biotechnology and Biological Sciences Research Council (BBSRC) and the University of Nottingham Institute for Enterprise and Innovation (UNIEI), is open to bioscience researchers and aims to help them commercialise their ideas.

The North West heat was held over three days at UMIC’s Core Technology Facility and Manchester United Football Club. Regional professionals, including representatives from The University of Manchester’s agent for intellectual property commercialisation (UMIP) and their network of advisors and professional associates offered mentoring sessions to the researchers during the competition. Teams also attended workshops and seminars to hear advice and received tips on how to develop their ideas into commercially-viable opportunities.

Each team was required to present an idea that is based on a hypothetical biotech idea.  On the final day of the event they presented their concept to a judging panel of biotechnology and business experts.

Dr Rich Ferrie, Director of IP commercialisation and Head of UMIP, commented: “This competition is a key part of the annual schedule of events at Manchester. It gives young bio scientists an opportunity to learn about business creation from a range of seasoned professionals, all of whom give their valuable time for free. This year’s competition attracted teams from right across the North of England, and even from London, and it was a pleasure to Chair one of the panels of judges and witness for myself how much the teams had learned in such a short period. We now wish the winning teams the best of luck for the UK Finals where they have every chance of overall success.”

Professor John Peberdy MBE, Emeritus Professor of Enterprise, UNIEI and originator of Biotechnology YES said: “Biotechnology YES was, and continues to be, a pioneering programme focussed on giving PhD students and early stage researchers, from all areas of the biosciences, an awareness of commercialisation processes and business relevant skills. In the seventeen years of its existence almost 4,000 research bioscientists have taken part in the Scheme. For many it has provided the focus for their career planning and development. In the latter years, significantly more than half the participants have looked to industry and business for their career.”

Arago Cross-Arm Technology Wins National Innovation Prize

Arago Technology Ltd was presented with the Power & Energy Award at the IET Innovation awards ceremony, which was held last Thursday at The Brewery, London.

The company, spun out from The University of Manchester by its technology transfer arm, UMIP, was awarded the prize by the judges in recognition of its work in developing the Insulating Cross-arm (ICA), which has the potential to enable electricity network operators to increase transmission capacity of existing lines. The ICA, which has been developed over the last 4 years, can be retro-fitted onto existing electricity pylons allowing voltage and / or current upgrade and may reduce the height of new build electricity pylons.

Arago’s revolutionary insulator was developed by engineers at the University in a joint venture with EPL Composite Solutions Ltd. The Insulating Cross-arms have been installed for over 2 years on pylons in some of the most stark and remote areas of the UK to test their resistance to extreme weather and since May ’12 they have also been continuously energised and monitored at voltages required for the 400,000 volt transmission network at a coastal site in northern Scotland.

Tests have also been carried out at the University’s High Voltage Laboratory which has subjected them to lightning strikes of more than 1.4 million volts.
Arago is currently seeking further investment to complete final development of this technology with deployment of the ICA orders already secured on the transmission system, commencing in 2014.

David Gardner, Director of Transmission for Scottish Hydro Electric Transmission plc said: "This innovative technology has the potential to deliver a cost effective way of increasing the power carried on our transmission network. We have worked closely with Arago to help develop the technology to the stage it has reached today and we are delighted to see that Arago have received this recognition for this work."

Robin MacLaren, designate chairman for Arago Technology Ltd said: “Winning the IET Award confirms that our innovative technology is world class and has the potential to deliver real solutions for society. We are very proud to have won this award and look forward to supporting the development of Transmission networks throughout the world to support the connection of new low carbon generation, and upgrade existing infrastructure.”

Ian Welch, innovation manager for National Grid, said: “Innovation will be vital for energy network companies as we meet the challenges from the huge changes underway in how we generate our electricity.  We have supported this project right from the early laboratory concept, so we are delighted to see it win the award.”

Project funding to-date by National Grid, Scottish Hydro Electric Transmission plc and The University of Manchester Intellectual Property's Proof-of-Principle Fund, managed by MTI partners, totals £2.5M.


Press contacts:

Clare Coyne, Roland Dransfield PR, 0161 236 1122 or clare.coyne@rdpr.co.uk

Gillian West, National Grid, 01926 655373 gillian.west@nationalgrid.com